The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company&#x27;s vascular intervention (VI) portfolio of VI devices includes laser and aspiration catheters; scoring balloon catheters, which supports catheters; and drug-coated balloon catheters. It also offers laser systems for use in various minimally invasive cardiovascular procedures; and sells, rents, and services its laser systems. The company&#x27;s primary crossing products include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme support catheters; and coronary vascular intervention products comprise ELCA Laser Ablation Catheter and AngioSculpt scoring balloon catheters for crossing and vessel preparation, as well as QuickCat aspiration catheter for thrombus management. Its lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories as well as Bridge occlusion balloon catheters for the removal of pacemaker and defibrillator cardiac leads. In addition, the company offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products directly, as well as through its distributors in the United States, Canada, Europe, the Middle East, the Asia Pacific, Japan, China, Russia, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.
